Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arman Arabshomali has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Analysis of the Utilization and Out‐of‐Pocket Costs of Authorized Generics and Independent Generics Among Medicare Beneficiaries

    by Arman Arabshomali, Kaustuv Bhattacharya, Sujith Ramachandran, Amit Patel, John P. Bentley

    Objective: To assess the utilization trends of authorized generics (AGs) within Medicare, evaluate differences in out‐of‐pocket (OOP) costs for Medicare beneficiaries between AGs and independent generics (IGs) when both were simultaneously available in the market, and estimate the adjusted mean difference in OOP costs between these generic types while controlling for potential confounders such as benefit phase and Medicare plan. Study Setting and Design: This retrospective analysis examined Medicare Part D claims from 2012 to 2020, focusing on prescription‐level OOP expenditures. Claims were limited to periods in which both AGs and IGs for the same product were concurrently available. Three measures of cost were used: per claim, per 30 units dispensed, and per 30‐day supply. Data Sources and Analytic Sample: Using the 5% national Medicare Part D sample, linked to the FDA National Drug Code (NDC) Directory, AGs, IGs, and their market availability were identified. Plan information was retrieved from Medicare Plan Characteristics files. Sensitivity analyses applied winsorized OOP costs for outliers and a two‐part model for excess zeros. Principal Findings: AGs comprised a small share of prescriptions and declined from 3.65% in 2012 to 2.30% in 2020. Compared to IGs, AGs incurred higher OOP costs across all measures. Median per 30‐day supply costs were $3.19 for AGs and $1.96 for IGs. Multivariable regression showed IGs had lower adjusted mean OOP costs, with differences of $4.32 per claim, $8.99 per 30 units dispensed, and $6.49 per 30‐day supply (all p < 0.0001). Results held across sensitivity analyses. Conclusions: Despite their smaller market share, AGs are associated with consistently higher OOP costs than IGs. These cost differences have important implications for Medicare affordability and generic market competition. Policies that ensure timely independent generic market entry and prevent anticompetitive delay tactics may help reduce beneficiary financial burden and improve access to lower‐cost generics.

  • Open Access

    History of drug pricing reform in the United States: from policy foundations to latest reforms

    by Sujith Ramachandran, Arman Arabshomali, John Coster

    This article examines the historical evolution of prescription drug pricing policy in the United States from the 1960s through 2025, highlighting how incremental reforms have produced a complex and fragmented system. It traces the foundations of drug pricing across Medicaid, Medicare, the Veterans Affairs (VA) system, and the 340B Drug Discount program, emphasizing the development of key pricing benchmarks such as Average Wholesale Price (AWP), Average Manufacturer Price (AMP), and Average Sales Price (ASP). The analysis details major legislative milestones affecting drug pricing, including the Omnibus Budget Reconciliation Act (OBRA) of 1990, the Medicare Modernization Act (MMA) of 2003, the Affordable Care Act (ACA) of 2010, and the Inflation Reduction Act (IRA) of 2022, and explains how these reforms reshaped reimbursement, rebates, cost of the prescription drugs, and access to medications. The article also identifies the various consequences of policy design, including the Medicaid “best price” provisions, growth in state Medicaid program supplemental rebates, and changes in prescription drug spending and reimbursement. Understanding the trajectory of policy reform is critical to identifying opportunities for improving affordability, access, and transparency in prescription drug markets.

  • Open Access

    Economic and humanistic burden of comorbid depression among individuals with irritable bowel syndrome in the non-institutionalized US adult population

    by Kaustuv Bhattacharya, Arman Arabshomali, Liang-Yuan Lin, Shadi Bazzazzadehgan, Queenie Paltanwale, Sushmitha Inguva, Swarnali Goswami


  • Concomitant use of prescription opioids and psychotropic medications: analysis of Mississippi Medicaid members

    by Arman Arabshomali, Omokhodion Alfred Eriakha, Liang-Yuan Claire Lin, Kaustuv Bhattacharya, Eric Pittman, John P. Bentley, Meg Pearson, Anna Kathryn Lambert, E. Ashton Smith, Jonathan Hubanks, et al.

    To estimate the prevalence and intensity of concomitant opioid and psychotropic medication use in Mississippi Medicaid members. This cross-sectional study used Mississippi Medicaid claims from 2016 to 2021 and examined members who filled at least one opioid prescription in a given year. The prevalence and intensity of concomitant opioid-psychotropic use, along with demographic characteristics, chronic non-cancer pain (CNCP) diagnoses, mental health diagnoses, and long-term opioid therapy (LTOT) among members were estimated annually. The eligible sample declined from 82,550 in 2016 to 51,583 in 2021, with CNCP diagnoses at 21% to 24% and LTOT use at 16% to 9%. Concomitant use prevalence was 33.3% in 2016 and 33.8% in 2021, with antidepressants (range: 14.46%-17.04%) and muscle relaxants (range: 13.92%-15.49%) being the most commonly used concomitant medications. Concomitant benzodiazepine use decreased over time (from 9.42% to 3.04%). Concomitant use intensity increased from 76.7% in 2016 to 84.3% in 2021, with mean increases for all studied medications. Despite reductions in opioid use, the stable prevalence and rising intensity of psychotropic medication overlap highlight a growing reliance on multimodal pharmacologic approaches. These findings underscore the importance of coordinated prescribing, ongoing monitoring, and targeted interventions to mitigate risks in vulnerable populations.

  • Shared Decision Making Interventions for Deprescribing in Older Adults With Polypharmacy: A Scoping Review

    by Soroush Fariman, Arman Arabshomali, Darshna Goordeen, Joshua D. Niznik, Homa Hemati, Jennifer Elston Lafata

    Background: Despite being integral to the deprescribing process, integration of shared decision making (SDM) into structured deprescribing interventions and its relation to patient outcomes remain understudied. Methods: We conducted a scoping review of PubMed/MEDLINE, Embase, Scopus, and PsycInfo (through September 2023) with a medical librarian's guidance. Studies of SDM interventions for deprescribing in older adults with polypharmacy were included. Two independent reviewers performed screening and data abstraction. An iterative narrative synthesis was conducted to categorize the core functions (purposes) and forms (specific activities) of the identified interventions, along with their measured outcomes, including SDM‐related outcomes. Results: Among 5402 retrieved records, 14 studies of 12 distinct interventions met the inclusion criteria. Studies were published between 2017 and 2023 and described a pilot implementation ( n = 3), randomized controlled trials ( n = 9), or patient interviews assessing perceptions regarding interventions ( n = 2). Most interventions ( n = 9) evaluated were specific to the outpatient setting and led by primary care physicians ( n = 6) or pharmacists ( n = 3). Two ( n = 2) were hospital‐based, involving pharmacists with nurse practitioners or physicians, and one ( n = 1) took place in nursing homes, led by nurses. Along with patient and medication identification ( n = 12) and SDM ( n = 12), common core functions included decision support ( n = 7), care coordination ( n = 5), coordinating follow‐up and monitoring ( n = 3), and family/caregiver involvement ( n = 2). Only 4 studies explicitly mentioned an SDM framework, the Three‐Talk Model ( n = 2), AHRQ SHARE ( n = 1), and the Collaborative Deliberation Model ( n = 1); only three ( n = 3) explicitly measured whether SDM occurred. The majority reported positive associations between the SDM interventions and medication use ( n = 6) and deprescribing behaviors ( n = 8). Conclusions: There is substantial variability in how deprescribing interventions incorporate SDM. Most studies do not empirically measure SDM. While SDM is associated with improved satisfaction and process of care outcomes, evidence regarding the impact of SDM‐informed deprescribing interventions and patient behavioral and health outcomes is inconclusive.


  • Open Access

    Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems

    by Masoud Salavati, Arman Arabshomali, Sasan Nouranian, Zia Shariat-Madar

    Venous thromboembolism (VTE) is a serious health condition and represents an important cause of morbidity and, in some cases, mortality due to the lack of effective treatment options. According to the Centers for Disease Control and Prevention, 3 out of 10 people with VTE will have recurrence of a clotting event within ten years, presenting a significant unmet medical need. For some VTE patients, symptoms can last longer and have a higher than average risk of serious complications; in contrast, others may experience complications arising from insufficient therapies. People with VTE are initially treated with anticoagulants to prevent conditions such as stroke and to reduce the recurrence of VTE. However, thrombolytic therapy is used for people with pulmonary embolism (PE) experiencing low blood pressure or in severe cases of DVT. New drugs are under development, with the aim to ensure they are safe and effective, and may provide an additional option for the treatment of VTE. In this review, we summarize all ongoing trials evaluating anticoagulant interventions in VTE listed in clinicaltrials.gov, clarifying their underlying mechanisms and evaluating whether they prevent the progression of DVT to PE and recurrence of thrombosis. Moreover, this review summarizes the available evidence that supports the use of antiplatelet therapy for VTE. Since thrombolytic agents would cause off-target effects, targeted drug delivery platforms are used to develop various therapeutics for thrombotic diseases. We discuss the recent advances achieved with thrombus-targeting nanocarriers as well as the major challenges associated with the use of nanoparticle-based therapeutics.


  • Open Access

    Medicines in Development for Venous Thromboembolism

    by Masoud Salavati, Arman Arabshomali, Sasan Nouranian, Zia Shariat-Madar

    Venous thromboembolism (VTE) is a serious health condition and represents an important cause of morbidity and, in some cases, mortality. According to the latest estimates from the Centers for Disease Control and Prevention, 3 out of 10 people with VTE will have recurrence of clotting event within 10 years. The American Heart Association reports that VTE is more common in people over 40 years of age, and that risk doubles with each decade. The World Health Organization advises that the world’s population of people aged 60 years is going to be doubled by 2050. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the two main conditions that make up VTE. People with VTE are initially treated with anticoagulants to prevent conditions such as stroke and to reduce the recurrence of VTE. However, thrombolytic therapy is used for people with PE experiencing with low blood pressure or in severe cases of DVT. Despite the approval of direct anticoagulants in 2010, there is clear evidence that the search for new drugs that are more effective or safer than the current antithrombotic treatments continues. Thrombin plays a crucial role in regulating hemostasis and maintaining blood coagulation, and therefore serves as a major target for the treatment of hemostatic disorders such as thromboembolic syndromes, disseminated intravascular coagulation, thrombocytopenia, and acquired hemostatic disorders such as platelet dysfunction and excessive anticoagulation, among other pathologies. This review focuses on the progress in research on new anticoagulants and novel delivery systems for antithrombotic targeting to vascular embolisms.

  • Open Access

    Potential Benefits of Antioxidant Phytochemicals in Type 2 Diabetes

    by Arman Arabshomali, Shadi Bazzazzadehgan, Fakhri Mahdi, Zia Shariat-Madar

    The clinical relationship between diabetes and inflammation is well established. Evidence clearly indicates that disrupting oxidant-antioxidant equilibrium and elevated lipid peroxidation could be a potential mechanism for chronic kidney disease associated with type 2 diabetes mellitus (T2DM). Under diabetic conditions, hyperglycemia, especially inflammation, and increased reactive oxygen species generation are bidirectionally associated. Inflammation, oxidative stress, and tissue damage are believed to play a role in the development of diabetes. Although the exact mechanism underlying oxidative stress and its impact on diabetes progression remains uncertain, the hyperglycemia-inflammation-oxidative stress interaction clearly plays a significant role in the onset and progression of vascular disease, kidney disease, hepatic injury, and pancreas damage and, therefore, holds promise as a therapeutic target. Evidence strongly indicates that the use of multiple antidiabetic medications fails to achieve the normal range for glycated hemoglobin targets, signifying treatment-resistant diabetes. Antioxidants with polyphenols are considered useful as adjuvant therapy for their potential anti-inflammatory effect and antioxidant activity. We aimed to analyze the current major points reported in preclinical, in vivo, and clinical studies of antioxidants in the prevention or treatment of inflammation in T2DM. Then, we will share our speculative vision for future diabetes clinical trials.


  • Open Access

    Targeting Oxidative Stress May Contribute to Improving the Inflammatory State and Glycemic Index of Glucose Control in Type 2 Diabetes

    by Arman Arabshomali, Shadi Bazzazzadehgan, Fakhri Mahdi, Zia Shariat-Madar

    The clinical relationship between diabetes and inflammation is well-established. Various branches of science independently have confirmed that disrupting oxidant-antioxidant equilibrium and elevated lipid peroxidation could be a potential mechanism for chronic kidney disease associated with Type 2 diabetes mellitus (T2DM). Under diabetic condition, hyperglycemia, especially inflammation, and increased reactive oxygen species generation are bidirectionally associated. Inflammation, oxidative stress and tissue damage are believed to have a role in the development of diabetes. Although the exact mechanism underlying the oxidative stress and its impact on diabetes progression remains uncertain, the hyperglycemia-inflammation-oxidative stress interaction clearly plays a significant role in onset and progression of vascular disease, kidney disease, hepatic injury, pancreas damage and, therefore holds promise as a therapeutic target. Evidence strongly indicates that the use of multiple antidiabetic medications therapy fails to achieve the normal range for glycated hemoglobin target, signifying treatment resistant diabetes. Antioxidants with polyphenols are considered useful as adjuvant therapy for their potential anti-inflammatory effect and antioxidant activity. We aimed to analyze the current major points reported in preclinical in vivo and clinical studies of antioxidants in the prevention or treatment of inflammation in T2DM. Then, we will share our speculative vision of the future diabetes clinical trials.